Clinical Application of Sulfhydryl Oxidase QSOX1 as a New Biomarker of Colon Cancer
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 400
- Primary Endpoint
- Detection of RNA for early rapid diagnosis of colon cancer.
Study Overview
Brief Summary
The goal of this observational study is to determine whether the secreted protein QSOX1 can be used as a molecular marker for early rapid diagnosis and accurate treatment of colon cancer.
Detailed Description
The project mainly selects the tumor group represented by colon cancer and the corresponding healthy people as the control group, with about 100 cases in each of the two groups. Mainly collect blood and tumor tissue samples of patients, detect the expression of QSOX1 in the above samples, and explore the role in the diagnosis and prognosis evaluation of colon cancer.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Colon cancer was confirmed by colonoscopic pathology.
- •No local or systemic treatment was performed before operation.
- •Complete clinical data.
Exclusion Criteria
- •Combined with benign diseases of colon, such as ulcerative colitis, colon adenoma and colon polyp.
- •Other tumors other than colon cancer.
Outcomes
Primary Outcomes
Detection of RNA for early rapid diagnosis of colon cancer.
Time Frame: 6 months
RT-PCR was used to detect the RNA levels of QSOX1 in the tumor and control groups.
Detection of protein for early rapid diagnosis of colon cancer.
Time Frame: 6 months
Western blotting was used to detect the protein levels of QSOX1 in the tumor and control groups.
Secondary Outcomes
No secondary outcomes reported
Investigators
YunqiuWang
Dr
Qianfoshan Hospital